Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled dose-finding study of MK-3207 for acute migraine
2008-001226-14Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-3207 in migraine (6 arms), sponsored by Merck & Co. Primary endpoints: Pain freedom at 2 hours postdose, Dose response for 2-hour pain freedom and 1 more. Started Jun 2008; status: completed.
02
Drugs
MK-3207
03
Conditions
migraine
Beyond the preview
Go deeper on 2008-001226-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001226-14.